Hepatic Colorectal Metastasis Pipeline

DelveInsight’s, “Hepatic - Colorectal Metastasis - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hepatic - Colorectal Metastasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Hepatic - Colorectal Metastasis: Understanding

Hepatic - Colorectal Metastasis: Overview

Colorectal cancer (CRC) is a significant global health issue, being the second most common cancer in women and the third in men, responsible for 10% of all cancer diagnoses and deaths worldwide. Advances in early detection, screening, surgery, chemotherapy, and understanding of tumor biology have improved survival rates. However, 25%-50% of CRC patients develop colorectal liver metastases (CRLM), which significantly impact treatment outcomes. Over time, the approach to managing CRLM has evolved, with surgical resection becoming a potentially curative treatment. Modern management of CRLM involves a multidisciplinary approach, including radiology, oncology, liver and colorectal surgery, histopathology, and nursing, all of which contribute to improved patient outcomes. This review explores the current strategies for diagnosing, staging, and treating CRLM, highlighting advances in chemotherapy, surgery, and biomarker use.

 

Colorectal cancer that has spread to the liver (hepatic metastases) can present with a range of symptoms, though some individuals may not experience noticeable signs, particularly in the early stages. Common symptoms include abdominal pain or discomfort, particularly in the upper right side, jaundice (yellowing of the skin and eyes), unexplained weight loss, fatigue, and a loss of appetite. Other potential signs include fever, nausea, swelling in the abdomen (ascites) or legs (edema), and general weakness. These symptoms, while indicative of liver involvement, can vary in severity depending on the extent of metastasis.

 

Genetic and environmental factors play a significant role in the development of colorectal cancer (CRC). While most cases are sporadic, around 15-20% of patients have a positive family history, with hereditary syndromes such as Lynch syndrome and familial adenomatous polyposis accounting for a smaller proportion. Lynch syndrome, caused by mutations in DNA repair genes, leads to an accumulation of genetic mutations and is often detected through PCR testing. Other genetic conditions, like Peutz-Jeghers syndrome and juvenile polyposis, also contribute to CRC risk. Additionally, chronic colitis is linked to 1% of cases. Environmental factors such as tobacco and alcohol consumption, obesity, diabetes, and diets high in red meat and processed foods increase CRC risk, with lifestyle factors responsible for a significant proportion of cases in Western populations. Preventive measures like anti-inflammatory treatments, statin use, and hormone replacement therapy for postmenopausal women may help reduce risk. 

 

The primary goal in managing colorectal cancer with hepatic metastases is to ensure the best possible quality of life and survival rate. Surgical resection of liver metastases remains the most effective treatment offering the potential for cure, especially in patients who are eligible for complete resection. However, the majority of patients with hepatic metastases are not candidates for surgery. In these cases, a combination of chemotherapy, including preoperative and adjuvant treatments, may help reduce tumors and potentially make them resectable. Chemotherapy regimens like FOLFOX4, FOLFIRI, and FOLFIRINOX have proven beneficial in both resectable and unresectable cases. For patients with unresectable liver metastases, regional treatments such as isolated hepatic perfusion (IHP), radiofrequency ablation, and chemoembolization offer alternative options. Despite advances, recurrence remains a challenge, with some patients requiring additional resection or treatment. Ultimately, a multidisciplinary approach, incorporating surgery, chemotherapy, and interventional techniques, is essential for improving outcomes in patients with hepatic metastases from colorectal cancer.

 

""Hepatic - Colorectal Metastasis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatic - Colorectal Metastasis pipeline landscape is provided which includes the disease overview and Hepatic - Colorectal Metastasis treatment guidelines. The assessment part of the report embraces, in depth Hepatic - Colorectal Metastasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatic - Colorectal Metastasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hepatic - Colorectal Metastasis R&D. The therapies under development are focused on novel approaches to treat/improve Hepatic - Colorectal Metastasis.

 

Hepatic - Colorectal Metastasis Emerging Drugs Chapters

This segment of the Hepatic - Colorectal Metastasis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Hepatic - Colorectal Metastasis Emerging Drugs

• Sotevtamab : Alethia Biotherapeutics 

Sotevtamab, is a humanized IgG2 monoclonal antibody that targets tumor-associated secreted clusterin (sCLU), a potent inducer of EMT. It is an inhibitor of the epithelial-to-mesenchymal transition (EMT), a key process in cancer metastasis. Preclinical studies have shown that sotevtamab potently inhibits EMT, leading to decreased tumor invasion and enhanced response to chemotherapy in animal models of cancer. Early clinical trials in patients with metastatic carcinoma refractory to conventional therapies have demonstrated good tolerability, safety, and clinical benefit for many patients, confirming the inhibition of EMT. Currently, the drug is in Phase II stage of its development for the treatment of Hepatic - Colorectal Metastasis.

 

• Nelitolimod: TriSalus Life Sciences, Inc.

Nelitolimod, an investigational agent in development, is a Toll-Like Receptor 9 (TLR9) agonist which is believed to bind to the TLR9 receptors found on suppressive immune cells including myeloid-derived suppressor cells (MDSCs), antigen-presenting immune cells and other immune cells. Toll-like receptors play a key role in the innate immune system and create a bridge to adaptive immunity. It is believed that activating TLR9 primes immune cells to promote anti-tumor T-cell function. Traditionally, TLR9 agonists like nelitolimod have not been administered intravenously but by direct injection into superficial tumors, making treatment of tumors in deep locations, like the liver and pancreas, difficult. TriSalus will utilize its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) method for intravascular regional delivery of nelitolimod to reach these locations. By infusing nelitolimod via this technology, Nelitolimod can be administered to visceral organs and directly to the site of disease. The goal of this approach is to enhance nelitolimod’s therapeutic index, increase anti-tumor immune activity intended to slow tumor progression and restore, enable or improve responses to immunotherapies for treatment of liver metastases. Currently, the drug is in Preclinical stage of its development for the treatment of Hepatic - Colorectal Metastasis.

Further product details are provided in the report……..

 

Hepatic - Colorectal Metastasis: Therapeutic Assessment

This segment of the report provides insights about the different Hepatic - Colorectal Metastasis drugs segregated based on following parameters that define the scope of the report, such as:

 

Major  Players in Hepatic - Colorectal Metastasis

There are approx. 3+ key companies which are developing the therapies for Hepatic - Colorectal Metastasis. The companies which have their Hepatic - Colorectal Metastasis drug candidates in the most advanced stage, i.e. Phase II include, Alethia Biotherapeutics.

 

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Hepatic - Colorectal Metastasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Hepatic - Colorectal Metastasis: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Hepatic - Colorectal Metastasis therapeutic drugs key players involved in developing key drugs. 

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatic - Colorectal Metastasis drugs.

 

Hepatic - Colorectal Metastasis Report Insights

• • Hepatic - Colorectal Metastasis Pipeline Analysis
• • Therapeutic Assessment
• • Unmet Needs
• • Impact of Drugs
•  

Hepatic - Colorectal Metastasis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hepatic - Colorectal Metastasis drugs?
• How many Hepatic - Colorectal Metastasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatic - Colorectal Metastasis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatic - Colorectal Metastasis therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Hepatic - Colorectal Metastasis and their status?
• What are the key designations that have been granted to the emerging drugs?